{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:57:01Z","timestamp":1787601421199,"version":"build-2736575974"},"reference-count":36,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"authors"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2022,3,4]]},"DOI":"10.1080\/14737140.2022.2037426","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:27:27Z","timestamp":1643779647000},"page":"269-274","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Naltrexone at low doses (LDN) and its relevance to cancer therapy"],"prefix":"10.1080","volume":"22","author":[{"given":"Wai M.","family":"Liu","sequence":"first","affiliation":[{"name":"Institute for Infection and Immunity, St George\u2019s University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus G","family":"Dalgleish","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George\u2019s University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5391"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0963689718811060"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00073-8"},{"issue":"1","key":"e_1_3_3_6_1","first-page":"108","article-title":"A complete regulatory loop between the immune and regulatory systems","volume":"44","author":"Blalock JE","year":"1985","unstructured":"Blalock JE, Smith EM. A complete regulatory loop between the immune and regulatory systems. Fed Proc. 1985;44(1):108\u2013111.","journal-title":"Fed Proc"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.1995.9.3"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-3806(86)90025-8"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(93)90194-Q"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<8::AID-SYN2>3.0.CO;2-Y"},{"issue":"23","key":"e_1_3_3_11_1","first-page":"5632","article-title":"Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth","volume":"55","author":"Hatzoglou A","year":"1995","unstructured":"Hatzoglou A, Ouafik L, Bakogeorgou E, et al. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res. 1995;55(23):5632\u20135636.","journal-title":"Cancer Res"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06321.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0225-3"},{"issue":"7","key":"e_1_3_3_14_1","first-page":"e2924","article-title":"Low dose naltrexone and lung cancer: a case report and discussion","volume":"10","author":"Miskoff JA","year":"2018","unstructured":"Miskoff JA, Chaudhri M. Low dose naltrexone and lung cancer: a case report and discussion. Cureus. 2018;10(7):e2924.","journal-title":"Cureus"},{"issue":"3","key":"e_1_3_3_15_1","first-page":"721","article-title":"Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3 - a case report","volume":"13","author":"Khan A","year":"2014","unstructured":"Khan A. Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3 - a case report. Oral Health Dent Manag. 2014;13(3):721\u2013724.","journal-title":"Oral Health Dent Manag"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735417747984"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735405285901"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735409352082"},{"issue":"3","key":"e_1_3_3_19_1","first-page":"255","article-title":"A new neuro-immunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone","volume":"23","author":"Lissoni P","year":"2002","unstructured":"Lissoni P, Malugani F, Bordin V, et al. A new neuro-immunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002;23(3):255\u2013258.","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.2174\/2589977513666210127094222"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31824babe2"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.12.011"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3567"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6867737"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106068"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106388"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1943"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557516666160505115743"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.4"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5020016"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.10.012"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13750"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.7.5.719-723.2000"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02904"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101028"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106718"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00809"},{"key":"e_1_3_3_38_1","first-page":"143","volume-title":"The LDN book: how a little-known generic drug \u2013 low Dose Naltrexone \u2013 could revolutionize treatment for autoimmune diseases, cancer, autism, depression, and more","author":"Dalgleish A","year":"2016","unstructured":"Dalgleish A, Liu W. Chapter 9 \u2013 cancer. In: Elsegood L, editor. The LDN book: how a little-known generic drug \u2013 low Dose Naltrexone \u2013 could revolutionize treatment for autoimmune diseases, cancer, autism, depression, and more. London: Chelsea Green Publishing; 2016. p. 143\u2013151."}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2022.2037426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T03:42:44Z","timestamp":1732074164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2022.2037426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,4]]}},"alternative-id":["10.1080\/14737140.2022.2037426"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2022.2037426","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}